Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded.

Carcinoma, Ductal / pathology Humans Male Neoplasm Grading Prostatic Neoplasms / pathology
ISUP grade Prostate adenocarcinoma intraductal carcinoma of prostate prognosis

Journal

Pathology
ISSN: 1465-3931
Titre abrégé: Pathology
Pays: England
ID NLM: 0175411

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 15 11 2019
accepted: 22 11 2019
pubmed: 18 12 2019
medline: 18 11 2020
entrez: 18 12 2019
Statut: ppublish

Résumé

Infiltration of the prostatic ducts by prostatic adenocarcinoma occurs relatively frequently, being most commonly associated with high grade disease. It is now recognised that intraductal carcinoma of the prostate (IDCP) has an associated poor prognosis and this is reflected in its histological, molecular and immunohistochemical features. The current recommendation of the World Health Organization is that IDCP not be taken into consideration when grading prostate adenocarcinoma. It is apparent that Gleason did not differentiate between IDCP and stromal invasive carcinoma when developing and validating his grading system, and recent studies suggest that the incorporation of IDCP grading into the overall grading of the specimen provides additional prognostic information.

Identifiants

DOI: 10.1016/j.pathol.2019.11.001 PMID: 31843189
pubmed: 31843189
pii: S0031-3025(19)30436-2
doi: 10.1016/j.pathol.2019.11.001
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

192-196

Informations de copyright

Copyright © 2019 Royal College of Pathologists of Australasia. All rights reserved.

Auteurs

Hemamali Samaratunga (H)

Aquesta Uropathology and University of Queensland, Brisbane, Qld, Australia.

Brett Delahunt (B)

Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand. Electronic address: brett.delahunt@otago.ac.nz.

Lars Egevad (L)

Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.

John R Srigley (JR)

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

Athanase Billis (A)

Department of Anatomic Pathology, School of Medical Sciences, State University of Campinas (Unicamp) Campinas, SP, Brazil.

David G Bostwick (DG)

Bostwick Laboratories, Orlando, FL, USA.

Philippe Camparo (P)

Department of Pathology, Centre de Pathologie Amiens, Amiens, France.

Liang Cheng (L)

Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.

David Clouston (D)

TissuPath, Mount Waverley, Vic, Australia.

James Denham (J)

School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.

Bungo Furusato (B)

Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences and Cancer Genomics Unit, Clinical Genomics Center, Nagasaki University Hospital, Sakamoto, Nagasaki, Japan.

Arndt Hartmann (A)

Institute of Pathology, University Erlangen-Nürnberg, Erlangen, Germany.

Laura Jufe (L)

Servicio de Anatomía Patológica. Hospital General de Agudos J.M. Ramos Mejía, Ciudad Autónoma de Buenos Aires, Argentina.

James Kench (J)

Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and Central Clinical School, University of Sydney, Sydney, NSW, Australia.

Diane N Kenwright (DN)

Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand.

Glen Kristiansen (G)

Institue of Pathology, Reference Centre for Uropathology, University Hospital Bonn, Bonn, Germany.

Katia R M Leite (KRM)

Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil.

Gregory T MacLennan (GT)

Department of Pathology and Urology, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Jennifer Merrimen (J)

Division of Anatomical Pathology, QEII Health Sciences Centre, Halifax, NS, Canada.

Holger Moch (H)

University and University Hospital Zurich, Department of Pathology and Molecular Pathology, Zurich, Switzerland.

Jon Oxley (J)

North Bristol NHS Trust, Bristol, UK.

Chin-Chen Pan (CC)

Department of Pathology, Taipei Veterans General Hospital, Taipei, Taiwan.

Gladell Paner (G)

Departments of Pathology and Surgery (Section of Urology) University of Chicago, Chicago, IL, USA.

Jae Ro (J)

Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Weill Medical College of Cornell University, Houston, TX, USA.

Isabell A M Sesterhenn (IAM)

Joint Pathology Center, Silver Spring, MD, USA.

Jonathan Shanks (J)

Department of Histopathology, The Christie NHS Foundation Trust, Manchester, UK.

Michelle Thunders (M)

Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand.

Toyonori Tsuzuki (T)

Department of Surgical Pathology, Aichi Medical University, School of Medicine, Nagakute, Japan.

Thomas Wheeler (T)

Department of Pathology and Laboratory Medicine, Baylor St. Luke's Medical Center and Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA.

John W Yaxley (JW)

Department of Medicine, University of Queensland, Wesley Urology Clinic, Royal Brisbane and Women's Hospital, Brisbane, Australia.

Murali Varma (M)

Department of Cellular Pathology, University Hospital of Wales, Cardiff, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Tumeurs canalaires, lobulaires et médullaires › Carcinome canalaire › Intraductal carcinoma of the prostate is an...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Intraductal carcinoma of the prostate is an...
questionsmedicales.fr › Diagnostic › Pronostic › Grading des tumeurs › Intraductal carcinoma of the prostate is an...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Intraductal carcinoma of the prostate is an...